Plzen 1

• A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden … Pending
  2025-523259-72-00 5 Hidradenitis Suppurativa (HS)
• A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Pending
  2025-524078-40-00 5 Chronic Spontaneous Urticaria
• An open label, randomized, multiple-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.T … Pending
  2025-524219-35-00 2 treatment of myasthenia gravis
• A Study to Evaluate the Effect of Obicetrapib and Ezetimibe Fixed-Dose Combination (FDC) or Obicetrapib on LDL-C in Participants With Type 2 … Recruiting
  2025-521936-12-00 5 2026-04-24 Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline re
• Long-Term Safety and Efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinica … Recruiting
  2023-506548-18-00 10 2022-11-10 Dermatitis atopic
• Efepoetin alfa for treatment of anemia in chronic kidney disease on dialysis Recruiting
  2023-503634-50-01 5 2025-07-22 Anemia in patients with chronic kidney disease on dialysis
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade … Ended recruitment
  2024-513266-19-00 5 2025-06-13 Hidradenitis Suppurativa (HS)
• A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in … Ended recruitment
  2023-508096-36-00 5 2024-10-30 atopic dermatitis
• 52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co … Ended recruitment
  2022-502161-19-00 5 2024-03-12 Chronic Spontaneous Urticaria
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• A bioequivalence study comparing Empagliflozin 25 mg film-coated tablets, VIANEX S.A., Greece versus Jardiance 25 mg film-coated tablets, Bo … Ended
  2025-524910-28-00 2 2026-03-09 none - healthy volunteers
• An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab … Ended
  2025-524218-27-00 2 2026-01-21 treatment of myasthenia gravis
• An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab … Ended
  2025-524217-89-00 2 2025-12-04 treatment of myasthenia gravis
• An open-label, randomized, single-dose, two-period, two-treatment, crossover bioequivalence study with GP-IMP-001 in healthy male volunteers … Ended
  2025-522921-37-00 2 2025-10-22 inteneded for treatment of - active rheumatoid arthritis in adult pati
• A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg … Ended
  2025-522562-70-00 2 2025-09-08 infection
• A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid f … Ended
  2025-521718-24-00 2 2025-07-28 infections
• A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Taromentin® 500 mg + 125 mg film- … Ended
  2025-521722-15-00 2 2025-06-26 infections
• An open label, randomized, single-dose, two-treatment, two-period, cross-over pilot bioequivalence study comparing Pyridostigmine Bromide, P … Ended
  2025-521177-14-00 2 2025-05-15 treatment of myasthenia gravis
• A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Dapagliflozin 10 mg film-coated t … Ended
  2024-520212-18-00 2 2025-04-03 intended for treatment of for the treatment of (2): • insufficiently
• A pilot, open label, single dose, randomized, four-period, four-sequence, four-treatment crossover, comparative bioavailability study of UDC … Ended
  2024-519920-26-00 2 2025-02-20 UDCA causes a reduction in cholesterol saturation of the bile by inhib
• Bioequivalence study of GP-IMP-001 with regards to reference product Ended
  2024-515889-14-00 2 2025-01-22 healthy volunteers
• A drug-drug interaction trial in healthy female participants to investigate the effect of aprocitentan on combined hormonal contraceptives. Ended
  2024-517224-19-00 3 2025-01-06 Not applicable - healthy volunteer trial
• The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatm … Ended
  2024-515436-76-00 2 2024-11-13 influenza

Showing 1–24 of 35 trials